Alpha Tau to present full HNSCC data after 75% ORR interim readout
The AHNS podium talk on July 21 will report complete results from a 48-patient Israeli study pairing Alpha DaRT radiation seeds with pembrolizumab in elderly head and neck cancer, building on an 8-patient interim look that showed a 75% objective response rate.
Executive Summary
- Alpha Tau will use a podium slot at a major head and neck oncology conference to disclose complete data from its combination study, moving the program from an interim look to a fuller readout.
- The presentation will show whether an intratumoral radiation device paired with a checkpoint inhibitor can sustain the response signal seen early in treatment-limited elderly patients, a population where standard multimodal therapy is often not an option.
- The study's earlier data cleared a high response bar in a small sample, so the complete data set will need to hold that response rate as enrollment matures, rather than drift back toward the historical response rate for checkpoint-inhibitor monotherapy in this disease.
- The pairing of a radiopharmaceutical device with a PD-1 inhibitor sits apart from the many antibody, ADC, and bispecific combinations being tested against PD-1 in this indication, giving the program little direct precedent to lean on.
The presentation
Alpha Tau said the abstract, titled "Management of Locally Advanced and Metastatic Head and Neck Squamous Cell Carcinoma in Elderly Patients Using Diffusing Alpha-Emitter Radiation Therapy in Combination with Pembrolizumab," was accepted for the Proffered Papers session on Radiation and Adjuvant Therapies, scheduled for 10:30 a.m. to 12:00 p.m. on July 21, 2026, in Boston. The company said the data are drawn from a single-center study at Hadassah Medical Center in Jerusalem, Israel, registered as NCT05047094. Alpha+1Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on ...May 5, 2026Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCNCT05047094
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The interim signal
An earlier readout from the same trial, presented at Alpha Tau's January 2025 R&D Update Day, reported an interim objective response rate of 75% (6 of 8 patients) and a complete response rate of 37.5% (3 of 8) in the first eight patients treated, with no serious adverse events attributed to Alpha DaRT as of the January 9, 2025 data cutoff. The company compared that response rate against historical benchmarks for pembrolizumab monotherapy in this setting. The July 21 presentation is described as complete top-line data, meaning the readout now extends beyond that initial eight-patient look toward the trial's full anticipated enrollment of 48 patients. NCT05047094+1Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCNCT05047094Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on ...May 5, 2026
Trial design
The study is a Not Applicable-phase, non-registrational, industry-sponsored interventional trial run in Israel, testing intratumoral Alpha DaRT radiation seeds added to standard-of-care pembrolizumab without altering the systemic regimen. Its registered primary endpoint is evaluation of efficacy of the DaRT and pembrolizumab combination, with duration of response, overall survival, and progression-free survival as secondary measures. The trial is recruiting, with a primary completion date of December 1, 2026, after that date shifted a year from an original December 2025 target in a single 2022 amendment. NCT05047094Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCCNCT05047094
The competitive frame
Pembrolizumab and other PD-1-targeting agents are being tested across 98 active trials in head and neck squamous cell carcinoma, and 45% of the 91 resolved PD-1-times-HNSCC trials on record have terminated rather than completed. Within that field, only 9 trials have used a radiopharmaceutical modality in this indication, and no other program pairs an intratumoral alpha-emitting radiation device with a checkpoint inhibitor in this specific elderly HNSCC population. Named PD-1 programs in adjacent tumors, including Merck's pembrolizumab studies and GlaxoSmithKline's dostarlimab program, share the target but not the radiopharmaceutical delivery mechanism, so they inform the checkpoint-inhibitor backbone rather than the DaRT combination itself.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.